BENEVICH ERIC 4

What Happened Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences (NBIX), had 2,294 restricted stock units (RSUs) vest and converted them into common shares on January 31, 2026. The company withheld 1,292 shares to satisfy tax withholding requirements at $136.06/share (tax value ≈ $175,790). No shares were sold on the open market; the transaction resulted in a net increase of 1,002 shares held by the reporting person.

Key Details

• Transaction date: January 31, 2026. Form 4 filed February 3, 2026.
• Conversion/exercise reported as derivative transaction (code M) for 2,294 shares at $0.00 exercise price.
• Tax withholding reported (code F): 1,292 shares withheld at $136.06/share, total ≈ $175,790. The filing notes no shares were sold to cover withholding.
• Net shares received: 2,294 converted − 1,292 withheld = +1,002 shares.
• Footnotes: RSUs were originally granted Jan 31, 2022 and vested in annual tranches (2,293 in 2023; 2,294 in 2024, 2025, and 2026).
• Filing does not indicate a late report.

Context

• This was vesting/conversion of RSUs (not an open-market purchase or sale). The withheld shares reflect a cashless tax-withholding arrangement common for RSU vesting and should be viewed as routine compensation-related activity rather than a directional insider trade.
• For retail investors, RSU vesting increases insider shareholdings but typically does not signal a deliberate buy or sell decision by the insider.